Sanofi has successfully concluded its acquisition of Inhibrx, Inc., enhancing its pipeline with SAR447537, a promising treatment for alpha-1 antitrypsin deficiency (AATD). Inhibrx shareholders approved the acquisition, valued at approximately $1.7 billion, entitling them to $30.00 per share in cash and potential additional payments. The transaction also involved a strategic spin-off, where Inhibrx Biosciences, acquiring all unrelated assets and employees, began trading as a separate entity on the NASDAQ. Sanofi was advised by Lazard and Weil, Gotshal & Manges LLP, while Centerview Partners LLC and Paul, Weiss, Rifkind, Wharton and Garrison LLP advised Inhibrx.

Pharmaceuticals, Biotechnology,France, United States